GSK plc (NYSE:GSK) Shares Acquired by Integrated Wealth Concepts LLC

Integrated Wealth Concepts LLC boosted its stake in GSK plc (NYSE:GSK) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 17,633 shares of the pharmaceutical company’s stock after purchasing an additional 627 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in GSK were worth $596,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the stock. Indiana Trust & Investment Management Co increased its holdings in shares of GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after buying an additional 500 shares during the last quarter. Crews Bank & Trust purchased a new stake in GSK during the fourth quarter valued at about $26,000. ST Germain D J Co. Inc. increased its stake in GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 522 shares during the last quarter. Sierra Ocean LLC purchased a new position in shares of GSK in the 4th quarter worth about $32,000. Finally, Parkside Financial Bank & Trust lifted its stake in shares of GSK by 470.1% in the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company’s stock valued at $34,000 after purchasing an additional 818 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Wall Street Analyst Weigh In

GSK has been the topic of several research reports. BNP Paribas started coverage on shares of GSK in a report on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 price target on the stock. Morgan Stanley initiated coverage on shares of GSK in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Hsbc Global Res upgraded GSK to a “strong sell” rating in a report on Monday. Finally, StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and four have given a strong buy rating to the stock. According to data from MarketBeat, GSK has an average rating of “Moderate Buy” and a consensus target price of $40.58.

GSK Stock Performance

NYSE:GSK opened at $38.75 on Friday. The firm has a 50-day moving average of $37.67 and a two-hundred day moving average of $36.04. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The stock has a market cap of $79.94 billion, a P/E ratio of 24.37, a PEG ratio of 1.12 and a beta of 0.56. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.93.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.05. GSK had a return on equity of 48.59% and a net margin of 8.13%. The firm had revenue of $10.06 billion during the quarter, compared to the consensus estimate of $7.52 billion. During the same quarter in the prior year, the business posted $0.43 earnings per share. GSK’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, research analysts expect that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, April 10th. Investors of record on Friday, February 21st were paid a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.06%. The ex-dividend date of this dividend was Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s payout ratio is 100.63%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.